Novel AML patient selection assay for AMV564, Amphivena’s lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting
- Sunday, December 6, 2020, 7:14
- PR Newswire
- Add a comment
SOUTH SAN FRANCISCO, Calif., Dec. 6, 2020 /PRNewswire/ — Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, today presented data on a novel assay for selection of acute myeloid leukemia (AML)…
About the Author
admin has written 20652 stories on this site.